SCHEMBL8340182

SCHEMBL8340182

COCCOCn1nc2c3c(c(O)ccc31)C(=O)c1ccccc1-2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TOP2A P11388 8/20 0.38
▸ FNTA P49354 1/20 0.36
▸ FNTB P49356 1/20 0.36
▸ MAPK13 O15264 1/20 0.36
▸ EIF2AK2 P19525 1/20 0.36
▸ MAPK12 P53778 1/20 0.36
▸ MAPK11 Q15759 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ USP8 P40818 1/20 0.34
▸ HPGD P15428 2/20 0.34
▸ MCL1 Q07820 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ CSNK1A1 P48729 1/20 0.34
▸ CSNK1D P48730 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8336928 0.87 ADORA2A (0.42) MAOAMEN1KMT2AMAPTTOP2A
SCHEMBL8336811 0.85 TOP2A (0.45) MAOAMEN1KMT2AMAPTTOP2A
SCHEMBL8172006 0.83 EIF2AK2 (0.54) MAOAMEN1KMT2AMAPTTOP2A
SCHEMBL8337451 0.76 TOP2A (0.45) MEN1KMT2AMAPTTOP2AMAPK13
SCHEMBL8340204 0.73 TOP2A (0.41) KMT2AMAPTTOP2AMAPK13EIF2AK2
SCHEMBL10800769 0.67 TOP2A (0.38) MAOAMAPTTOP2ASMN1; SMN2
SCHEMBL10805231 0.65 TOP2A (0.54) MEN1KMT2AMAPTTOP2AFNTA
SCHEMBL18984751 0.64 CYP19A1 (0.51) MAOAMEN1KMT2AMAPTTOP2A
SCHEMBL4399257 0.64 CYP19A1 (0.51) MAOAMEN1KMT2AMAPTTOP2A
SCHEMBL10801104 0.63 TOP2A (0.54) TOP2AFNTAFNTBMAPK13EIF2AK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335676-B2 Methods for treating inflammatory conditions or inhibiting JNK SIGNAL PHARMACEUTICALS, LLC (US) 2008-02-26 — — US disclosed
WO-2004084891-A1 METHODS FOR TREATING INFLAMMATORY CONDITIONS OR INHIBITING JNK SIGNAL PHARMACEUTICALS, LLC (US) 2004-10-07 — — WO disclosed
Send feedback